NCT03377023View on ClinicalTrials.gov

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

February 2, 2018

Primary Completion Date

November 28, 2023

Study Completion Date

November 30, 2025

Conditions
Non Small Cell Lung CancerLung Cancer, Nonsmall CellNon Small Cell Lung Cancer Metastatic
Interventions
DRUG

Nivolumab

Intravenous nivolumab every 2 weeks.

DRUG

Ipilimumab

Intravenous ipilimumab every 6 weeks.

DRUG

Nintedanib

Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT03377023 - Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter